Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)

BIOLOGICAL3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Hai Li, Cytopeutics Sdn. Bhd.

Conditions

Acute-On-Chronic Liver FailureMesenchymal Stem CellsOsteoarthritis, KneeThrombocytopenia

Phase 2

Safety of UC-MSC Transfusion for ACLF Patients

Hai LiAcute-On-Chronic Liver Failure

Start: 2021-09-30End: 2024-07-21Target: 16Updated: 2021-07-21

Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury

CompletedNCT05016011

Cytopeutics Sdn. Bhd.Osteoarthritis, Knee

Start: 2020-07-01End: 2022-03-21Updated: 2024-01-03

Unknown Phase

Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for Treatment of Refractory Immune Thrombocytopenia

CompletedNCT04014166

Institute of Hematology & Blood Diseases Hospital, ChinaMesenchymal Stem Cells, Thrombocytopenia

Start: 2019-11-21End: 2023-06-30Updated: 2025-02-21

Related Papers

Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial.

2024-04-2326 citations

Efficacy and Safety of Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Immune Thrombocytopenia: A Prospective, Single Centre, Single Arm, Phase I Trial

Blood2023-11-022 citations

Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

Blood2022-11-151 citations